Evidence map›Paper›PMID 38557171›Full record

ArticleAntimicrobial agents and chemotherapy2024

Liang Chen, Elena Shashkina, Natalia Kurepina, Vinicius Calado Nogueira de Moura, Charles L Daley, Barry N Kreiswirth

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evolution toward extremely high imipenem resistance inAntimicrobial agents and chemotherapy · 2024
    Article
  5. Evolution towards extremely high β-lactam resistance inbioRxiv : the preprint server for biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Liang ChenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0001-5845-2235
Elena ShashkinaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Natalia KurepinaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Vinicius Calado Nogueira de MouraDepartment of Medicine, National Jewish Health, Denver, Colorado, USA.ORCID 0000-0001-5874-0958
Charles L DaleyDepartment of Medicine, National Jewish Health, Denver, Colorado, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0243-131X
Hackensack Meridian Health · USNational Jewish Health · US

Funding

Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complexR01AI141805 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI BARRY Neal KREISWIRTH · 2019 to 2026
$5.1M
NIAID NIH HHS R01 AI141805
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsBoronic AcidsCefoxitinCeftarolineCephalosporinsImipenemMeropenemMicrobial Sensitivity TestsMycobacterium abscessusbeta-Lactamase InhibitorsHumansMycobacterium Infections, NontuberculousAnti-Bacterial Agentsbeta-Lactamase InhibitorsBoronic AcidsCefoxitinCeftarolineCephalosporinsImipenemMeropenemvaborbactamCRISPR interferenceMycobacterium abscessuspeptidoglycan synthesisvaborbactamβ-lactamase inhibitors

Identifiers

PMID38557171
PMCPMC11064484
OpenAlexW4393387314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.